Format

Send to

Choose Destination
BMC Public Health. 2017 Oct 3;17(1):769. doi: 10.1186/s12889-017-4703-z.

Using automated voice messages linked to telephone counselling to increase post-menstrual regulation contraceptive uptake and continuation in Bangladesh: study protocol for a randomised controlled trial.

Author information

1
Department of Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. kate.reiss@lshtm.ac.uk.
2
Ipas, P.O. Box 9990, Chapel Hill, NC, 27515, USA.
3
Centre for Global Health and Health Partnerships, School of Population Sciences and Health Services Research, King's College London, Room 2.63 Weston Education Centre, Cutcombe Road, London, SE5 9RJ, UK.
4
Population Council, One Dag Hammarskjold Plaza, New York, NY, 10017, USA.
5
Ipas Bangladesh, Eureka Saleha Palace, (Flat - B2 & C2), 2nd Floor, House #2F-1-3, Mymensingh Road, Shahbag, Dhaka, 1000, Bangladesh.
6
Department of Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
7
Department of Medical Statistics, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
8
MRC Clinical Trials Unit at UCL, Aviation House, Kingsway, London, UK.
9
Evidence to Action Team, Health Systems Department, Marie Stopes International, London, W1T 6LP, UK.
10
Independent Consultant, Dhaka, Bangladesh.
11
Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA.

Abstract

BACKGROUND:

Adoption of modern contraceptive methods after menstrual regulation (MR) is thought to reduce subsequent unwanted pregnancy and abortion. Long-acting reversible contraceptives (LARCs) are highly effective at reducing unintended pregnancy, but uptake in Bangladesh is low. Providing information on the most effective methods of contraception increases uptake of more effective methods. This protocol describes a randomised controlled trial of an intervention delivered by mobile phone designed to support post-MR contraceptive use in Bangladesh.

METHODS:

This is a multi-site single blind individual randomised controlled trial. At least 960 women undergoing MR procedures at selected facilities will be recruited after their procedure by female research assistants. Women will be randomised into the control or intervention group with a 1:1 ratio. All participants will receive usual clinic care, including contraceptive counselling and the telephone number of a non-toll-free call centre which provides counselling on MR and contraception. During the 4 months after their MR procedure, intervention participants will be sent 11 recorded interactive voice messages to their mobile phone about contraception with a focus on their chosen method and LARCs. Each message allows the participant to connect directly to the call centre. The intervention is free to the user. The control group will receive no messages delivered by mobile phone. All participants will be asked to complete an in-person questionnaire at recruitment and follow-up questionnaires by telephone at 2 weeks, 4 months and 12 months after their MR. The primary outcome for the trial will be self-reported LARC use 4 months post-MR. Secondary outcomes include LARC use at 2 weeks and 12 months post-MR, use of any effective modern contraceptive method at 2 weeks, 4 months and 12 months post-MR, and contraceptive discontinuation, contraceptive method switching, pregnancy, subsequent MR and experience of violence during the 12 month study period.

DISCUSSION:

Mobile phones offer a low-cost mechanism for providing individualised support to women with contraception outside of the clinic setting. This study will provide information on the effects of such an intervention among MR clients in Bangladesh.

TRIAL REGISTRATION:

Trial registered with clinicaltrials.gov Registration number: NCT02579785 Date of registration: 16th October 2015.

KEYWORDS:

Abortion; Bangladesh; Contraception; Family planning; Mobile phone; Post-menstrual regulation; Protocol; Randomised controlled trial; mHealth

PMID:
28974209
PMCID:
PMC5627401
DOI:
10.1186/s12889-017-4703-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center